NICE's Rejection of Celgene's Abraxane Puts Spotlight On Cost Again
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE's rejection of Celgene's Abraxane for pancreatic cancer on cost grounds could increase calls for a review of the agency’s end-of-life criteria policy.